Will the FDA approve an AI-based clinical trial consent form translation tool by March 31, 2027?

This market resolves to Yes if, during or as a direct result of the AI Radiology Symposium announced on September 24, 2026, at least one AI-based medical tool or software is revealed to have been cleared by the U.S. Food and Drug Administration (FDA) by October 15, 2026. Public confirmation from the symposium organizers, participating companies, or the FDA itself must be available for the resolution.

This market resolves to Yes if peer-reviewed study results published by March 2027 show that the dual-drug strategy significantly improves clinical outcomes (such as progression-free survival or overall response rate) for patients with triple-negative breast cancer compared to current standard treatments.

This market resolves to Yes if the proposed combination of healthcare providers Atrium and WakeMed receives approval from the relevant regulatory authorities by February 2027. The approval must be publicly confirmed by that date.

This market resolves to Yes if the US National Institutes of Health (NIH) publicly announces new guidelines specifically aimed at exercise for adults aged 65 and older by December 31, 2026. The announcement must be reported by a credible health or governmental news source.

This market resolves to Yes if the National Committee for Quality Assurance (NCQA) officially implements new quality measures developed in partnership with Komodo Health AI by February 28, 2027. The implementation must be publicly announced by NCQA or verifiable through reliable healthcare industry news sources.

This market resolves to Yes if Medicaid enrollment in Illinois, as reported by the Illinois Department of Healthcare and Family Services, decreases by more than 10% from its current figures by December 31, 2027.